Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: Safety and preliminary activity of the open-label, single-arm, phase II ARCADIA trial

被引：2
|
作者：
Marandino, L. [1 ]
Raggi, D. [1 ]
Giannatempo, P. [1 ]
Calareso, G. [2 ]
Alessi, A. [3 ]
Colecchia, M. [4 ]
Madison, R. [5 ]
Ross, J. S. [6 ]
Necchi, A. [1 ]
机构：
[1] Ist Nazl Tumori Milano Fdn IRCCS, Dept Med Oncol, Milan, Italy
[2] Ist Nazl Tumori Milano, Fdn IRCCS, Radiol, Milan, Italy
[3] Ist Nazl Tumori Milano Fdn IRCCS, Nucl Med, Milan, Italy
[4] Ist Nazl Tumori Milano Fdn IRCCS, Pathol, Milan, Italy
[5] Fdn Med Inc, Clin Bioinformat Operat, Cambridge, MA USA
[6] Fdn Med Inc, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
773P
引用
收藏
页码：S595 / S595
页数：1
相关论文
共 50 条
  • [1] Cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 ARCADIA trial
    Marandino, L.
    Raggi, D.
    Giannatempo, P.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (12) : 900 - 900
  • [2] Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial
    Marandino, L.
    Raggi, D.
    Calareso, G.
    Alessi, A.
    Colecchia, M.
    Martini, A.
    Briganti, A.
    Montorsi, F.
    Madison, R.
    Ross, J. S.
    Necchi, A.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 457 - 465
  • [3] Clinical safety and activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) after platinum chemotherapy (ARCADIA): Preliminary results from a nonrandomized, open-label, phase 2 trial.
    Giannatempo, Patrizia
    Franza, Andrea
    Marandino, Laura
    Raggi, Daniele
    Calareso, Giuseppina
    Alessi, Alessandra
    Colecchia, Maurizio
    Bevilacqua, Liana
    Russo, Giusy
    Del Re, Marzia
    Anichini, Andrea
    Sgambelluri, Francesco
    Sepe, Pierangela
    Zimatore, Matteo
    Claps, Melanie
    Verzoni, Elena
    Guadalupi, Valentina
    Ottini, Arianna
    Procopio, Giuseppe
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma of urothelial and non-urothelial histology: An open-label, single-arm, phase 2 trial.
    Necchi, Andrea
    Giannatempo, Patrizia
    Raggi, Daniele
    Anichini, Andrea
    Calareso, Giuseppina
    Crippa, Flavio
    Mariani, Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
    Giannatempo, P.
    Bottiglieri, A.
    Guadalupi, V.
    Marandino, L.
    Raggi, D.
    Stellato, M.
    Rametta, A.
    Baciarello, G.
    Sepe, P.
    Claps, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Cattaneo, L.
    Verzoni, E.
    Ortega, C.
    Procopio, G.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1205
  • [6] Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.
    Giannatempo, Patrizia
    Guadalupi, Valentina
    Marandino, Laura
    Raggi, Daniele
    Stellato, Marco
    Rametta, Alessandro
    Baciarello, Giulia
    Bottiglieri, Achille
    Sepe, Pierangela
    Claps, Melanie
    Buti, Sebastiano
    Stefania, Pipitone
    Iacovelli, Roberto
    Calareso, Giuseppina
    Alessi, Alessandra
    Cattaneo, Laura
    Verzoni, Elena
    Procopio, Giuseppe
    Mariani, Luigi
    Necchi, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with cabozantinib (CABO) plus durvalumab (DURVA): Preliminary analysis from the phase 2 ARCADIA trial.
    Giannatempo, Patrizia
    Sgambelluri, Francesco
    Stellato, Marco
    Guadalupi, Valentina
    Raggi, Daniele
    Rametta, Alessandro
    Bottiglieri, Achille
    Claps, Melanie
    Walter, Ferrari Bravo
    Oldani, Simone
    Zimatore, Matteo
    Calareso, Giuseppina
    Alessi, Alessandra
    Cattaneo, Laura
    Verzoni, Elena
    De Braud, Filippo G.
    Procopio, Giuseppe
    Necchi, Andrea
    Anichini, Andrea
    Mortarini, Roberta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 684 - 684
  • [8] Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
    Giannatempo, P.
    Polymeropoulos, A.
    Stellato, M.
    Ambrosini, P.
    Gusmaroli, E.
    Cavalli, C.
    Guadalupi, V.
    Claps, M.
    Raggi, D.
    Rametta, A.
    Ortega, C.
    Tucci, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Procopio, G.
    Miceli, R.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1161 - S1161
  • [9] Cabozantinib plus durvalumab in patients with advanced and chemotherapy- treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
    Stellato, M.
    Giannatempo, P.
    Polymeropoulos, A.
    Guadalupi, V.
    Claps, M.
    Ambrosini, P.
    Raggi, D.
    Rametta, A.
    Cavalli, C.
    Gusmaroli, E.
    Ortega, C.
    Tucci, M.
    Buti, S.
    Pipitone, S.
    Iacovelli, R.
    Calareso, G.
    Alessi, A.
    Procopio, G.
    Miceli, R.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S1146 - S1146
  • [10] Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: The phase 2 ARCADIA trial.
    Mereu, Alessandro
    Salsetta, Jeannette
    Lalli, Luca
    Squarcina, Paola
    Banfi, Cristina
    Sgambelluri, Francesco
    Mortarini, Roberta
    Huber, Veronica
    Stellato, Marco
    Raggi, Daniele
    Guadalupi, Valentina
    Claps, Melanie
    Bottiglieri, Achille
    Walter, Ferrari Bravo
    Calareso, Giuseppina
    Alessi, Alessandra
    Procopio, Giuseppe
    Necchi, Andrea
    Rivoltini, Licia
    Giannatempo, Patrizia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 687 - 687
12345